Skip to navigation Skip to content

Severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD) program in Pharmaceutical Benefits Scheme (PBS) 012-22092336



This document outlines details of PBS-subsidised mecasermin for patients with severe growth failure with primary insulin-like growth factor-1 deficiency (IGFD).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Severe growth failure with primary IGFD quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB336 form

Written

Electronic

S100:

mecasermin

No

OPA

Must be treated and prescribed by a:

  • specialist in paediatric endocrinology
  • paediatrician in consultation with a specialist in paediatric endocrinology

Yes

Continuing

PB337 form

Written

Electronic

S100:

mecasermin

No

OPA

Must be treated and prescribed by a:

  • specialist in paediatric endocrinology
  • paediatrician in consultation with a specialist in paediatric endocrinology

Yes